NASDAQ:KOOLCesca Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cesca Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.64 +0.11 (+2.43 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$4.32Now: $4.64▼$4.6950-Day Range$4.30MA: $5.28▼$6.4052-Week Range$2.10Now: $4.64▼$7.00Volume870,129 shsAverage Volume96,680 shsMarket Capitalization$11.23 millionP/E RatioN/ADividend YieldN/ABeta1.07 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCesca Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, Cesca Therapeutics has a potential upside of 61.6% from its current price of $4.64.Amount of Analyst CoverageCesca Therapeutics has received no research coverage in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesCesca Therapeutics has received 267 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCesca Therapeutics has received 224 “underperform” votes. (Add your “underperform” vote.)Community SentimentCesca Therapeutics has received 54.38% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cesca Therapeutics and other stocks. Vote “Outperform” if you believe KOOL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KOOL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCesca Therapeutics does not currently pay a dividend.Dividend GrowthCesca Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cesca Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders68.90% of the stock of Cesca Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.11% of the stock of Cesca Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cesca Therapeutics are expected to grow in the coming year, from ($0.26) to $0.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cesca Therapeutics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cesca Therapeutics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCesca Therapeutics has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.57 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Laboratory apparatus & furniture Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KOOL Previous Symbol CUSIPN/A CIK811212 Webwww.cescatherapeutics.com Phone916-858-5100Debt Debt-to-Equity Ratio0.50 Current Ratio1.52 Quick Ratio0.91Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$9.67 million Price / Sales1.16 Cash FlowN/A Price / Cash FlowN/A Book Value$3.11 per share Price / Book1.49Profitability EPS (Most Recent Fiscal Year)($3.60) Net Income$-39,720,000.00 Net Margins-98.84% Return on Equity-77.30% Return on Assets-37.75%Miscellaneous Employees53 Outstanding Shares2,420,000Market Cap$11.23 million Next Earnings DateN/A OptionableNot Optionable $4.64 +0.11 (+2.43 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive KOOL News and Ratings via Email Sign-up to receive the latest news and ratings for KOOL and its competitors with MarketBeat's FREE daily newsletter. Cesca Therapeutics (NASDAQ:KOOL) Frequently Asked Questions How has Cesca Therapeutics' stock price been impacted by COVID-19? Cesca Therapeutics' stock was trading at $3.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KOOL stock has increased by 38.1% and is now trading at $4.64. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Cesca Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cesca Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cesca Therapeutics. How were Cesca Therapeutics' earnings last quarter? Cesca Therapeutics Inc (NASDAQ:KOOL) issued its quarterly earnings results on Monday, May, 14th. The biotechnology company reported ($0.27) EPS for the quarter. The biotechnology company earned $1.87 million during the quarter. Cesca Therapeutics had a negative net margin of 98.84% and a negative return on equity of 77.30%. View Cesca Therapeutics' earnings history. What price target have analysts set for KOOL? 1 analysts have issued 1-year price objectives for Cesca Therapeutics' stock. Their forecasts range from $7.50 to $7.50. On average, they expect Cesca Therapeutics' share price to reach $7.50 in the next twelve months. This suggests a possible upside of 61.6% from the stock's current price. View analysts' price targets for Cesca Therapeutics. Has Cesca Therapeutics been receiving favorable news coverage? Press coverage about KOOL stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cesca Therapeutics earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news about Cesca Therapeutics. Who are some of Cesca Therapeutics' key competitors? Some companies that are related to Cesca Therapeutics include IsoRay (ISR), AgeX Therapeutics (AGE), InMed Pharmaceuticals (IN), Jaguar Health (JAGX), Newron Pharmaceuticals (NWPHF), Zelda Therapeutics (ZLD), Inspiration Healthcare Group (IHC), Zhongchao (ZCMD), Invion (IVX), Biotricity (BTCY), HTG Molecular Diagnostics (HTGM), Zivo Bioscience (ZIVO), Addex Therapeutics (ADDXF), Forward Pharma A/S (FWP) and AIkido Pharma (AIKI). View all competitors. What other stocks do shareholders of Cesca Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cesca Therapeutics investors own include CTI BioPharma (CTIC), SCYNEXIS (SCYX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), AbbVie (ABBV), AEterna Zentaris (AEZS), Anavex Life Sciences (AVXL), BioDelivery Sciences International (BDSI) and Amicus Therapeutics (FOLD). Who are Cesca Therapeutics' key executives? Cesca Therapeutics' management team includes the following people: Dr. Xiaochun Xu M.B.A., Ph.D., Chairman, CEO & Pres (Age 48)Mr. Jeff Cauble, Principal Financial & Accounting Officer (Age 46)Mr. James Xu J.D., L.L.M., M.B.A., Director, Gen. Counsel, Sr. VP of Legal Affairs & Cybersecurity and Corp. Sec. (Age 48)Mr. Philip H. Coelho, Chief Technology Officer (Age 75)Ms. Haihong Zhu, Pres of ThermoGenesis What is Cesca Therapeutics' stock symbol? Cesca Therapeutics trades on the NASDAQ under the ticker symbol "KOOL." How do I buy shares of Cesca Therapeutics? Shares of KOOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cesca Therapeutics' stock price today? One share of KOOL stock can currently be purchased for approximately $4.64. How big of a company is Cesca Therapeutics? Cesca Therapeutics has a market capitalization of $11.23 million and generates $9.67 million in revenue each year. The biotechnology company earns $-39,720,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. Cesca Therapeutics employs 53 workers across the globe. What is Cesca Therapeutics' official website? The official website for Cesca Therapeutics is www.cescatherapeutics.com. How can I contact Cesca Therapeutics? Cesca Therapeutics' mailing address is 2711 CITRUS ROAD, RANCHO CORDOVA CA, 95742. The biotechnology company can be reached via phone at 916-858-5100 or via email at [email protected] This page was last updated on 8/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
